# ProQR Therapeutics N.V.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/ProQR Therapeutics N.V.).

## Overview

ProQR Therapeutics N.V. is a clinical-stage biotechnology company focused on discovering and developing RNA-based therapeutics. The company is organized around a single reportable segment and advances drug candidates for diseases with significant unmet medical need, including cholestatic and other genetic conditions.

## Products & services

• RNA-based therapeutic discovery and development
• Clinical-stage drug candidates for rare and specialty diseases
• Preclinical and translational research programs
• Clinical trial design and execution support

- **RNA therapeutics** (100%) — Discovery and development of RNA-based medicines aimed at disease-causing genetic pathways.

- RNA-based therapeutic discovery and development
- Clinical-stage drug candidates for rare and specialty diseases
- Preclinical and translational research programs
- Clinical trial design and execution support

## Customers

ProQR does not sell a broad commercial product portfolio; its primary counterparties are clinical trial sites, investigators, regulators, and development partners that support its drug programs. The eventual end users are patients with rare, genetic, or cholestatic diseases, while the economic value of the programs is typically realized through partnering, licensing, or future commercialization.

- **Clinical development ecosystem** (primary) — Investigators, sites, CROs, and regulators involved in advancing clinical programs and obtaining approvals.
- **Pharmaceutical partners** (secondary) — Potential collaborators or licensees that may fund, develop, or commercialize RNA programs.
- **Patients with rare diseases** (primary) — Patients in cholestatic and genetic disease indications targeted by the company’s pipeline.

- Clinical trial investigators and sites running ProQR studies
- Regulators reviewing CTA and trial approvals
- Potential pharmaceutical partners and licensees
- Patients with rare genetic and cholestatic diseases
- Specialist physicians treating inherited disease populations

## Geography

ProQR is headquartered in the United States and operates as an international biotech organization, with reportable activities centered on research and clinical development. The excerpts specifically reference a European CTA approval for AX-0810, indicating that Europe is an important geography for clinical execution and regulatory interaction. As a development-stage company, geography matters mainly through trial locations, regulatory pathways, and access to specialized clinical sites rather than manufacturing footprint.

- **United States** (50%) — Headquarters and corporate base
- **Europe** (50%) — Clinical development and regulatory activity; CTA approved in Europe

- Headquartered in the United States
- Clinical and regulatory activity spans multiple jurisdictions
- Europe is relevant for trial approvals and patient enrollment
- Geography affects where trials can be run and approved

## Strategy

ProQR’s strategy is to build value through a focused RNA-therapeutics pipeline, with emphasis on cholestatic disease programs and other genetically defined opportunities. The company’s approach relies on generating human proof-of-concept data, progressing clinical milestones, and creating optionality for partnering or future commercialization.

- **Advance AX-0810 through early clinical development** (short-term) — Human data are the main value inflection points for a clinical-stage biotech.
- **Focus on cholestatic disease opportunities** (medium-term) — Concentrating on a defined therapeutic area can improve scientific focus and development efficiency.
- **Expand value beyond a single lead asset** (medium-term) — Pipeline breadth can reduce dependence on one clinical outcome and improve partnering leverage.

- Advance cholestatic disease programs through clinical milestones
- Generate target-engagement and proof-of-concept data
- Use focused pipeline execution to conserve development capital
- Build partnering optionality around differentiated RNA assets

## Risks

As a clinical-stage biotechnology company, ProQR faces high development risk because its value depends on successful clinical results, regulatory approvals, and eventual partnering or commercialization. The company also carries going-concern and funding risk typical of pre-revenue drug developers, while broader biotech risks include trial delays, safety findings, and uncertainty in translating early data into later-stage success.

- **Clinical development failure** [critical] — Pipeline value depends on proving that RNA candidates work in humans.
- **Safety or tolerability issues** [high] — Dose escalation and continuation depend on acceptable safety findings.
- **Going-concern and financing risk** [high] — Development-stage biotech companies consume cash before meaningful product revenue.
- **Regulatory timing risk** [medium] — Trial approvals and data readouts can shift based on agency review and protocol execution.

- Clinical trials may fail to show efficacy or target engagement
- Safety signals can halt dose escalation or delay development
- Funding needs depend on continued access to capital
- Regulatory approvals may not be obtained on expected timelines
- Single-asset concentration increases program-specific downside

## Accounting

ProQR’s reporting is shaped by clinical-stage biotech accounting, where most spending is expensed as research and development and future value is highly judgmental. Management also discloses a going-concern assessment, and the company’s estimates depend on assumptions about timing and status of services, which can shift quarterly results. Because there is no established product revenue base in the excerpts, investors should focus on how clinical program costs, accruals, and fair-value judgments affect reported losses and cash burn.

- **Clinical trial accruals** — Can cause quarterly expense true-ups
- **Going concern** — Important for solvency and disclosure assessment
- **Research and development expense** — Main driver of reported loss and cash burn

- Research and development expense drives most operating spend
- Accruals depend on estimated timing of clinical services
- Going-concern assessment reflects funding and cash runway
- Judgmental estimates can shift period-to-period results
- No product revenue recognition is disclosed in the excerpts

---

*Last updated: 2026-09-28T12:13:44.894338+00:00*